Tag:

Sandoz

Latest Headlines

Latest Headlines

Novartis whacks 3 Sandoz plants, 770 jobs, despite generic units' sales growth

A 10% revenue expansion in Novartis' generics unit Sandoz was one of the positives in the Swiss drugmaker's second quarter earnings, but it will not keep the drugmaker from closing three Sandoz plants next year and cutting about 770 jobs to improve margins even more.

Sandoz gives Novartis a boost, but 3 plants still get the boot

Novartis's generics business Sandoz provided the key bright spot in an otherwise tough earnings report for the Swiss pharma, with revenues up 10%. But the starring performance did not keep the manufacturing side of Sandoz from getting spanked, with three of its plants now targeted for closing.

Amgen's Neupogen won't face Novartis biosim till September: court

Novartis' Sandoz may have the first FDA-approved biosimilar in Zarxio, but it doesn't have permission to launch--and it won't be getting that until September, the country's top patent court ruled Tuesday.

Look out, Teva--Novartis' Copaxone generic is off to a speedy start

The launch for Glatopa, the new generic of Teva's Copaxone from Novartis' Sandoz, is still in the very early going. But so far, things look good--very good.

Novartis' Sandoz puts India plant on chopping block

Novartis CEO Joe Jimenez said in March the company would have another go at significant cost cuts in the wake of its asset swap with GlaxoSmithKline. Manufacturing was one area where it expected to tighten up, and a plant in India is now on the chopping block along with 170 jobs.

Sandoz recalls 1M units of generic Zyrtec made in India

Novartis CEO Joe Jimenez took a swipe at Sandoz's Indian competitors last year, suggesting there would be fallout in the generics market as smaller players were unable to "build quality into their systems" to meet rising regulatory demands. Now a Sandoz plant in India is having its own issues, recalling more than 1 million packages of a generic of the number one selling allergy pill Zyrtec.

Novartis asks court to take the brakes off Neupogen biosim

Last month, a U.S. appeals court blocked Novartis' biosimilar version of Amgen's blockbuster Neupogen while the companies worked out a patent dispute. Unsurprisingly, though, Novartis wants that ban lifted, and now it's asking the court to do just that.

Novartis' Sandoz expands Poland plant with packaging facility

Novartis' plant in Stryków, Poland, one of the largest of its Sandoz generics unit, had no packaging lines, forcing the company to transport its production to other facilities for that step in the supply chain. Sandoz will be able to expand capacity at the plant and save on transportation costs now that it has opened a new packaging facility there.

Momenta/Sandoz Copaxone generic may be the only one around for a while, exec says

Generics makers have been champing at the bit to get a copy out of Teva's Copaxone, the best-selling multiple sclerosis med that generated $4.2 billion in revenue last year. But according to Momenta CEO Craig Wheeler, his company's version--a joint effort with partner Sandoz, Novartis' generics unit--may be the only knockoff around for a while.

What price MS therapy? Thanks to price hikes, $50K-plus, even for decades-old meds

The cost of multiple sclerosis drugs has skyrocketed over the past 20 years, and it's not just new drugs driving that increase. Not one MS drug has a list price of less than $50,000 per year in the U.S., and some treatments cost 7 times more now than they did in 1995, a new study found.